FDA feedback on the new brilaroxazine formulation, expected in Q4 2026, is the next major catalyst. The company's ability to secure additional financing will determine whether RECOVER-2 enrollment can begin in 1H 2027. Monitor for any partnership announcements that could extend cash runway.
Drugs in focus
RVPH drug pipeline →brilaroxazine
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
- Next catalyst
- None dated
What to watchThe immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.
Price Chart
Executive Summary
Reviva reported Q3 2026 net loss of $2.3M ($0.17 per share), narrower than the $4.0M loss in Q3 2025. Cash stood at $17.5M. The company expects FDA feedback in Q4 2026 on a new brilaroxazine formulation, with RECOVER-2 Phase 3 enrollment contingent on additional financing. The stock trades on OTCQB after Nasdaq delisting.
Key Financial Metrics
Key Facts
- Net loss of $2.3M ($0.17 per share) for Q3 2026, vs $4.0M ($1.09) in Q3 2025
- Cash and cash equivalents of $17.5M as of September 30, 2026
- FDA feedback on new brilaroxazine formulation expected Q4 2026
- RECOVER-2 Phase 3 enrollment expected 1H 2027, subject to additional financing
- U.S. patent office granted priority examination (Track 1) for new formulation patent
- Company anticipates filing for Nasdaq relisting in 1H 2027
- Common stock currently quoted on OTCQB after Nasdaq delisting
Financial Impact
Q3 2026 net loss $2.3M vs $4.0M in Q3 2025; cash burn rate ~$1.5M per quarter
Risk Factors
- Nasdaq delisting completed; OTCQB trading may reduce liquidity and access to capital
- RECOVER-2 enrollment contingent on additional financing; cash runway may be insufficient
- No revenue; pre-commercial stage with no approved products
- FDA feedback on new formulation could delay or alter clinical development path
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-036647 |
| Document: 0001437749-26-036647-index-headers.html | 0001437749-26-036647 |
| Document: 0001437749-26-036647-index.html | 0001437749-26-036647 |
| Document: 0001437749-26-036647.txt | 0001437749-26-036647 |
| 8-K Data (Synthetic) | 0001437749-26-036647 |
Track record
12 reports on RVPH
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Viewing No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3533 Now $0.3504 −0.81% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers